Centrus Reports Second Quarter 2026 Results

Centrus Energy reported Q2 2026 revenue of $176.1M (+14% YoY) and adjusted net income of $38.7M (adjusted EPS $1.95), despite GAAP net income falling to $16.8M (-42% YoY). The company signed a $900M DOE HALEU enrichment award contract, grew enrichment backlog to $3.0B, and selected Geiger Brothers to expand the uranium enrichment plant; it also signed a first-of-a-kind, large-scale commercial HALEU supply agreement with potential prepayments. Management raised 2026 hiring guidance (≥100 net new hires in Oak Ridge and ≥175 in Piketon) and expects its first new centrifuge to be completed by year-end 2026 in Oak Ridge, supporting improved SWU pricing momentum.

Analysis

LEU is becoming less of a quarter-to-quarter earnings story and more of a strategic scarcity asset. The market should value the business on how quickly management can convert milestone-based backlog into financed, contractable capacity; that supports a higher multiple only if execution is clean and customer prepayments reduce external capital needs. The second-order winners are the industrial contractors and niche equipment suppliers tied to centrifuge buildout, while the likely losers are utilities and advanced-reactor developers if HALEU pricing tightens before new supply is online, because they will face higher fuel-cycle costs before they get the benefit of assured availability.

The near-term catalyst path is not the reported backlog itself but DOE appropriation language, any exercise of additional task orders, and proof that the first new centrifuge actually lands on schedule. Over 1-3 months, the stock can fade if investors focus on rising capex and working-capital absorption rather than backlog growth; over 6-18 months, execution at Piketon/Oak Ridge is the real driver of whether this becomes a self-funded industrial expansion or a capital-intensive promise. The biggest falsifier is any slippage in construction milestones, a weaker-than-expected 2027 federal funding profile, or signs that prepayments are not material.

Consensus may be underestimating how much of the announced commercial strength is conditional, not earned. This is not a clean FCF compounder yet: the balance sheet is being asked to fund industrial buildout while stock comp and growth costs suppress reported earnings, so the equity can still be range-bound if the market decides the cash conversion is too slow. The contrarian read is that the strongest trade may be to own LEU as a scarcity winner, but only against a hedge that removes uranium price beta; otherwise you are paying for execution optionality plus macro fuel sentiment at the same time.

Key Decisions for Investors

• Long LEU on post-open weakness, with a 1-3 month horizon, but size modestly: thesis is milestone-driven rerating, not near-term FCF; trim if the stock fails to hold the first consolidation area after the print.
• Pair trade: long LEU / short CCJ for 1-3 months to isolate enrichment scarcity from uranium price beta; this works if SWU pricing tightens faster than U3O8 contracts reprice.
• If implied volatility is elevated, prefer LEU call spreads over outright stock for the next DOE/capex milestone window; the risk is capped if construction or funding headlines disappoint.
• Set an alert for any DOE 2027 funding commentary or shutdown risk: a negative budget signal would likely cap the multiple quickly and is the cleanest falsifier of the backlog-to-cash thesis.
• Watch for capex and working-capital burn in the next two quarters; if operating cash flow stays negative while expansion spend rises, use that as a signal to fade the rally rather than add.